Dermatomyositis and lupus may share symptoms in some cases. Here's what you need to know about these autoimmune conditions.

Pharmacologic therapies are the cornerstone of dermatomyositis management, aimed at reducing inflammation, suppressing autoimmunity, and preventing disease progression. Treatment strategies are ...

Treatment with dazukibart, a monoclonal antibody targeting interferon beta, yielded a rapid reduction in dermatomyositis disease activity in adults with skin-predominant and muscle-predominant ...

Received FDA orphan drug designation for the treatment of dermatomyositis in April 2017. Received FDA approval for the treatment of dermatomyositis in adults in July 2021. The mechanism of action ...